|
|
|
| home | genetic news | bioinformatics | biotechnology | literature | journals | ethics | positions | events | sitemap |
Hydroxyurea Therapy Improves Survival in Most Severely Affected Sickle Cell Patients
|
Sickle cell anemia patients who took the drug hydroxyurea over a 9-year period experienced a 40 percent reduction in deaths, according to the first study to evaluate whether the treatment prolongs life, announced the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
The study of 299 adult sickle cell patients with moderate to severe forms of the disease, found that improved survival was related to the benefits associated with hydroxyurea treatment — an increase in fetal hemoglobin and reduced episodes of severe pain “crises” and chest syndrome, a pneumonia-like illness. The results were published in the April 2 issue of The Journal of the American Medical Association. CONTACT:
Message posted by: Rashmi Nemade
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser. Use the links below to share this article on the social bookmarking site of your choice. Read more about social bookmarking at Wikipedia - Social Bookmarking |
BioGPS: a centralized online resource for gene annotation Brain Adaptations to Sensory Loss Sequencing Small Chips A Stroke Against Stroke Inhibition Present in Absences Assessing Natural Memory Variant Associated with Alcoholic Liver Disease Parkinson's Gene Mutated in Cancer Mismatch Associated with Graft-Versus-Host-Disease High Levels of HLA-C Associated with Slower HIV/AIDS Progression Feeding Back on Tumour Initiation more news ... |
Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S. Zollmann.
7.0 © 1995-2010 HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint.